1,760 results on '"Preudhomme, Claude"'
Search Results
2. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study
3. Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
4. Prognostic impact of CEBPA mutational subgroups in adult AML
5. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
6. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL
7. Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group
8. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression
9. Negative Impact of TET2 Mutations on Long-Term Survival After Transcatheter Aortic Valve Replacement
10. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
11. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
12. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia
13. Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group
14. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
15. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
16. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
17. Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
18. Publisher Correction: Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
19. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
20. Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
21. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
22. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
23. A multiparametric niche-like drug screening platform in acute myeloid leukemia
24. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis
25. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
26. Prognostic impact of CEBPA mutational subgroups in adult AML
27. A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis
28. Monitoring molecular changes in the management of myelodysplastic syndromes.
29. Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AML.
30. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease
31. Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
32. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
33. Clonal Dynamics of FLT3-ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin
34. Impact of Residence in an Agricultural Zone on AML Characteristics
35. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
36. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
37. Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia
38. Familial myeloid malignancies with germline TET2 mutation
39. Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes
40. Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia
41. Three UBA1 clones for a unique VEXAS syndrome
42. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
43. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
44. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia
45. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia
46. Clinical impact of genetic alterations including germline DDX41mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
47. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML
48. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones
49. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
50. Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.